Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older

被引：0
|
作者：
Angel Vila-Corcoles
Olga Ochoa-Gondar
Jorge A Guzmán
Teresa Rodriguez-Blanco
Elisabet Salsench
Cruz M Fuentes
机构：
[1] Institut Catalá de la Salut,Primary Care Service of Tarragona
[2] IDIAP Jordi Gol Foundation,Valls
[3] Rovira i Virgili University,Department of Epidemiology and Biostatistics
来源：
BMC Infectious Diseases | / 10卷
关键词：
Influenza; Risk Stratum; Influenza Vaccination; Vaccine Effectiveness; Invasive Pneumococcal Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Andrews, Nick J.
    Waight, Pauline A.
    George, Robert C.
    Slack, Mary P. E.
    Miller, Elizabeth
    VACCINE, 2012, 30 (48) : 6802 - 6808
  • [2] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
    Nielsen, Katrine Finderup
    Nielsen, Lise Birk
    Lomholt, Frederikke Kristensen
    Norgaard, Sarah Kristine
    Slotved, Hans-Christian
    Dalby, Tine
    Fuursted, Kurt
    Jorgensen, Charlotte Svaerke
    Valentiner-Branth, Palle
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (12) : 1473 - 1477
  • [3] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
    Katrine Finderup Nielsen
    Lise Birk Nielsen
    Frederikke Kristensen Lomholt
    Sarah Kristine Nørgaard
    Hans-Christian Slotved
    Tine Dalby
    Kurt Fuursted
    Charlotte Sværke Jørgensen
    Palle Valentiner-Branth
    European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 1473 - 1477
  • [4] Relative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia
    Takashima, Mari
    Lambert, Stephen B.
    Paynter, Stuart
    Ware, Robert S.
    VACCINE, 2019, 37 (12) : 1638 - 1641
  • [5] Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence
    Niederman, Michael S.
    Folaranmi, Temitope
    Buchwald, Ulrike K.
    Musey, Luwy
    Cripps, Allan W.
    Johnson, Kelly D.
    EXPERT REVIEW OF VACCINES, 2021, 20 (03) : 243 - 255
  • [6] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [7] Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study
    Leventer-Roberts, Maya
    Feldman, Becca S.
    Brufman, Ilan
    Cohen-Stavi, Chandra J.
    Hoshen, Moshe
    Balicer, Ran D.
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (10) : 1472 - 1480
  • [8] 23-valent pneumococcal polysaccharide vaccine and the risk of renal progression in older patients with chronic kidney disease
    Chang, Po-Ya
    Lin, Chun-Ji
    Chen, Hao-Cheng
    Fan, Hueng-Chuen
    Kuo, Hsuchung
    PREVENTIVE MEDICINE, 2023, 177
  • [9] Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults
    Hsiao, Amber
    Lewis, Ned
    Hansen, John
    Timbol, Julius
    Suaya, Jose A.
    Alexander-Parrish, Ronika
    Grant, Lindsay R.
    Gessner, Bradford D.
    Klein, Nicola P.
    VACCINE, 2025, 44
  • [10] Cost effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
    Jiang, Yiling
    Gauthier, Aline
    Annemans, Lieven
    van der Linden, Mark
    Nicolas-Spony, Laurence
    Bresse, Xavier
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (05) : 645 - 660
12345